Welcome to our dedicated page for Hepion Pharmaceuticals SEC filings (Ticker: CTRVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Hepion Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Hepion Pharmaceuticals's regulatory disclosures and financial reporting.
Hepion Pharmaceuticals, Inc. (HEPA) entered into securities purchase agreements with certain accredited investors for a private placement of 8,000,000 shares of common stock and warrants to purchase 8,000,000 shares of common stock at an offering price of $0.05 per share, for gross proceeds of $400,000. The warrants are exercisable at an exercise price of $0.06 per share for a term of five years from issuance. The securities are being issued in an unregistered private offering relying on Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, and may not be offered or sold in the United States without registration or an applicable exemption. The agreements include customary representations, warranties, conditions to closing, indemnification obligations, and termination provisions.
Hepion Pharmaceuticals, Inc. (HEPA) reported that Interim CEO and director Gary S. Stetz received a grant of stock options for 1,345,500 shares of common stock. The options have an exercise price of $0.08 per share and expire on August 19, 2036. According to the grant terms, 336,375 options vest immediately, and the remaining options vest in equal monthly installments over six months from the grant date.
Hepion Pharmaceuticals, Inc. (HEPA) reported that Executive Chairman Vincent S. LoPriore received a grant of stock options on 2026-08-19. The award covers 1,345,500 options to acquire common stock at an exercise price of $0.08 per share, expiring on 2036-08-19. According to the footnote, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over six months from the grant date. Following this grant, LoPriore holds 1,345,500 stock options directly.
Hepion Pharmaceuticals, Inc. (HEPA) reported that director and officer Chase LoPriore, VP, Corp. Dev., received a grant of stock options for 1,345,500 shares of Common Stock on August 19, 2026. The options have a conversion or exercise price of $0.08 per share and expire on August 19, 2036. According to the vesting terms, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over six months from the grant date. Following this grant, LoPriore holds 1,345,500 stock options directly.
Hepion Pharmaceuticals, Inc. (HEPA) reported that director James Gordon Liddy received a grant of stock options. The award covers 299,000 stock options, each for one share of common stock, with an exercise price of $0.08 per share, exercisable from August 19, 2027 until August 19, 2036. Following this grant, he holds 299,000 stock options directly.
Hepion Pharmaceuticals, Inc. (HEPA) reported that Chief Operating Officer and director Appajosyula Sireesh received a grant of stock options for 1,345,500 shares of Common Stock on 2026-08-19. The options have a conversion/exercise price of $0.08 per share, expire on 2036-08-19, and are held directly. According to the vesting terms, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over 6 months from the grant date, leaving Sireesh with 1,345,500 options outstanding following this award.
Hepion Pharmaceuticals, Inc. (HEPA) reported that director Gary S. Stetz II received a grant of 299,000 stock options on August 19, 2026. The options have an exercise price of $0.08 per share, are exercisable beginning August 19, 2027, and expire on August 19, 2036. Following this grant, he holds 299,000 derivative securities directly.
Hepion Pharmaceuticals, Inc. (HEPA) reported an initial statement of beneficial ownership for director Liddy James Gordon on a Form 3. The filing lists no equity transactions, derivative positions, or specific share holdings for this reporting person at the time of filing.
Hepion Pharmaceuticals, Inc. (HEPA) announced that its Board of Directors appointed James Liddy as a director, effective August 19, 2026. The company states there are no arrangements or understandings with any other person regarding his selection and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
The report is signed on behalf of Hepion Pharmaceuticals by Gary Stetz, Interim Chief Executive Officer, dated August 20, 2026. No financial results or transactional developments are included in this disclosure; it is focused on corporate governance and board composition.
Hepion Pharmaceuticals, Inc. (HEPA) had a Schedule 13D filed by director and Chief Operating Officer Sireesh Appajosyula, reporting beneficial ownership of 5,250,000 shares of common stock, including 2,000,000 shares issuable upon exercise of warrants. This represents 5.7% of Hepion’s common stock, based on 90,219,317 shares outstanding as of August 10, 2026.
The filing states an aggregate purchase price of approximately $150,000 for the securities. On April 21, 2026 he acquired 1,250,000 shares for $50,000, and on July 31, 2026 he acquired 2,000,000 shares plus a warrant for 2,000,000 shares for $100,000. The warrant is immediately exercisable at $0.06 per share, subject to a Beneficial Ownership Limitation. The stake is described as acquired for investment purposes, with no additional specific corporate plans disclosed.